Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | Chief Financial Officer | August 12, 2026 | August 17, 2026 |
| Perfumania Holdings, Inc.PERF · Entity 172127 | CFO | April 28, 2017 | May 05, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edgewise Therapeutics, Inc.
Report date August 12, 2026 · Filed August 17, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2036-08-12 | Direct | 48,750 |
Reported balance
After 2026-08-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-08-12 · Grant · Acquired 48,750 · Balance 48,750 F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Perfumania Holdings, Inc.
Report date April 28, 2017 · Filed May 05, 2017
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SpringWorks Therapeutics, Inc.
Report date July 01, 2025 · Filed July 02, 2025
Section 16 reporting ended · disclosed 2025-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 1
1 source rowRow 1 · 2025-07-01 · Disposition to issuer · Disposed 30,623 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F2: Includes 19,682 shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock. F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration"). F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date. |
| Performance Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-01 · Disposition to issuer · Disposed 8,661 · Balance 0 F5: Represents restricted share units subject to performance-based vesting conditions (each, a "PSU") granted under the Plan. Each PSU represents a contingent right to receive one share of Issuer common stock. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.45 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-01 · Disposition to issuer · Disposed 78,300 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.64 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-01 · Disposition to issuer · Disposed 65,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.40 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-07-01 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.00 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-07-01 · Disposition to issuer · Disposed 20,246 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger").
F2: Includes 19,682 shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock.
F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration").
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date.
F5: Represents restricted share units subject to performance-based vesting conditions (each, a "PSU") granted under the Plan. Each PSU represents a contingent right to receive one share of Issuer common stock.
F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement.
F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)
F8: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 14, 2026 20:54 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 48,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001705477-26-000001 · primarydocument.xml · derivative · entry 2 Nofi Michael · CIK 0001705477 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 48,750 shares Expires 2036-08-12 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:54 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 24,375 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001705477-26-000001 · primarydocument.xml · derivative · entry 1 Nofi Michael · CIK 0001705477 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,375 Underlying: Common Stock · 24,375 shares Expires 2036-08-12 F1 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027. Read SEC document |
| August 12, 2026 Filed Aug 17, 2026 22:41 UTC Amendment | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 48,750 | $0.00 Strike: $43.56 | $0.00 |
DisclosureSEC source: 0001705477-26-000002 · primarydocument.xml · derivative · entry 1 Nofi Michael · CIK 0001705477 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 48,750 shares Expires 2036-08-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 23:03 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Options (Right to buy) · Derivative | 262,500 | $0.00 Strike: $18.28 | $0.00 |
DisclosureSEC source: 0001705477-25-000005 · primarydocument.xml · derivative · entry 2 Nofi Michael · CIK 0001705477 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,500 Underlying: Common Stock · 262,500 shares Expires 2035-11-10 F2 · derivative.exercise_date: 1/4th of the shares subject to the option become vested and exercisable on November 10, 2026 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 23:03 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 43,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001705477-25-000005 · primarydocument.xml · derivative · entry 1 Nofi Michael · CIK 0001705477 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Stock · 43,750 shares Expires 2035-11-10 F1 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on November 10, 2026. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:20 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,246 | Not disclosed Strike: $43.00 | Not disclosed |
DisclosureSEC source: 0001104659-25-065302 · tm2519678-5_4seq1.xml · derivative · entry 6 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,246 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:20 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $38.40 | Not disclosed |
DisclosureSEC source: 0001104659-25-065302 · tm2519678-5_4seq1.xml · derivative · entry 5 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:20 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 65,000 | Not disclosed Strike: $27.64 | Not disclosed |
DisclosureSEC source: 0001104659-25-065302 · tm2519678-5_4seq1.xml · derivative · entry 4 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:20 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 78,300 | Not disclosed Strike: $25.45 | Not disclosed |
DisclosureSEC source: 0001104659-25-065302 · tm2519678-5_4seq1.xml · derivative · entry 3 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,300 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · price: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.exercise_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8) F8 · derivative.expiration_date: (Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:20 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerPerformance Share Units · Derivative | 8,661 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-065302 · tm2519678-5_4seq1.xml · derivative · entry 2 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,661 shares Expires not disclosed F5 · derivative.exercise_price: Represents restricted share units subject to performance-based vesting conditions (each, a "PSU") granted under the Plan. Each PSU represents a contingent right to receive one share of Issuer common stock. F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement. F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:20 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerCommon Stock | 30,623 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-065302 · tm2519678-5_4seq1.xml · nonDerivative · entry 1 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F2 · shares: Includes 19,682 shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration"). F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 21:35 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantStock Option (Right to Buy) · Derivative | 20,246 | $0.00 Strike: $43.00 | $0.00 |
DisclosureSEC source: 0001104659-25-003466 · tm253183-6_4seq1.xml · derivative · entry 2 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,246 Underlying: Common Stock · 20,246 shares Expires 2035-01-10 F2 · derivative.exercise_date: This option shall vest in forty-eight (48) equal monthly installments following January 10, 2025, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 21:35 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantCommon Stock | 6,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-003466 · tm253183-6_4seq1.xml · nonDerivative · entry 1 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,623 F1 · kind: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 10, 2026, another thirty-three percent (33%) to vest on January 10, 2027 and the remaining thirty-four percent (34%) to vest on January 10, 2028, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. F1 · shares: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 10, 2026, another thirty-three percent (33%) to vest on January 10, 2027 and the remaining thirty-four percent (34%) to vest on January 10, 2028, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 00:16 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 1,009 | $38.86 | $39,209.74 |
DisclosureSEC source: 0001104659-25-001773 · tm252237-5_4seq1.xml · nonDerivative · entry 3 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,694 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 00:16 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 1,636 | $38.19 | $62,478.84 |
DisclosureSEC source: 0001104659-25-001773 · tm252237-5_4seq1.xml · nonDerivative · entry 2 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,703 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| January 04, 2025 Filed Jan 8, 2025 00:16 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 2,388 | $38.19 | $91,197.72 |
DisclosureSEC source: 0001104659-25-001773 · tm252237-5_4seq1.xml · nonDerivative · entry 1 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,339 F1 · security: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 02:11 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 1,063 | $41.53 | $44,146.39 |
DisclosureSEC source: 0001104659-24-002376 · tm242462-5_4seq1.xml · nonDerivative · entry 3 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,727 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person. F2 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 02:11 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 1,169 | $37.96 | $44,375.24 |
DisclosureSEC source: 0001104659-24-002376 · tm242462-5_4seq1.xml · nonDerivative · entry 2 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,790 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person. F2 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 04, 2024 Filed Jan 9, 2024 02:11 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001104659-24-002376 · tm242462-5_4seq1.xml · derivative · entry 4 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-01-03 F3 · derivative.exercise_date: This option shall vest in forty-eight (48) equal monthly installments following January 4, 2024, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. Read SEC document |
| January 04, 2024 Filed Jan 9, 2024 02:11 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantCommon Stock | 14,104 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-002376 · tm242462-5_4seq1.xml · nonDerivative · entry 1 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,959 F1 · security: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. F1 · kind: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. F1 · shares: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date. Read SEC document |
| January 07, 2023 Filed Jan 10, 2023 21:08 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 409 | $26.41 | $10,801.69 |
DisclosureSEC source: 0001104659-23-002719 · tm232960-7_4seq1.xml · nonDerivative · entry 1 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,855 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock awards and does not represent a sale by the Reporting Person. F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock awards and does not represent a sale by the Reporting Person. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 22:00 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 783 | $27.52 | $21,548.16 |
DisclosureSEC source: 0001104659-23-002314 · tm232787-4_4seq1.xml · nonDerivative · entry 2 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,264 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. F2 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 22:00 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $27.64 | $0.00 |
DisclosureSEC source: 0001104659-23-002314 · tm232787-4_4seq1.xml · derivative · entry 4 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-01-05 F4 · derivative.exercise_date: Twenty-five percent (25%) of this option shall vest and become exercisable on January 5, 2024, with the remaining seventy-five percent (75%) to vest in thirty-six (36) equal monthly installments thereafter subject to continued service to the Issuer by the Reporting Person. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 22:00 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $27.64 | $0.00 |
DisclosureSEC source: 0001104659-23-002314 · tm232787-4_4seq1.xml · derivative · entry 3 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-01-05 F3 · derivative.exercise_date: This option shall vest in 48 equal monthly installments subject to continued service to the Issuer by the Reporting Person. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 22:00 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantCommon Stock | 9,713 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-002314 · tm232787-4_4seq1.xml · nonDerivative · entry 1 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,047 F1 · security: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 5, 2024, another thirty three percent (33%) to vest on January 5, 2025 and the remaining thirty four percent (34%) to vest on January 5, 2026, such that the restricted stock awards are fully vested on January 5, 2026. F1 · kind: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 5, 2024, another thirty three percent (33%) to vest on January 5, 2025 and the remaining thirty four percent (34%) to vest on January 5, 2026, such that the restricted stock awards are fully vested on January 5, 2026. F1 · price: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 5, 2024, another thirty three percent (33%) to vest on January 5, 2025 and the remaining thirty four percent (34%) to vest on January 5, 2026, such that the restricted stock awards are fully vested on January 5, 2026. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:03 UTC | SpringWorks Therapeutics, Inc. [SWTX · Entity 15910 | Tax withholdingCommon Stock | 567 | $56.06 | $31,786.02 |
DisclosureSEC source: 0001104659-22-003145 · tm222586d4_4.xml · nonDerivative · entry 1 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,181 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock awards and does not represent a sale by the Reporting Person. Read SEC document |
| January 07, 2022 Filed Jan 14, 2022 21:59 UTC Amendment | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Tax withholdingCommon Stock | 414 | $56.06 | $23,208.84 |
DisclosureSEC source: 0001104659-22-004467 · tm223052-7_4aseq1.xml · nonDerivative · entry 1 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,334 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock awards and does not represent a sale by the Reporting Person. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 21:22 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantStock Option (Right to Buy) · Derivative | 17,913 | $0.00 Strike: $59.46 | $0.00 |
DisclosureSEC source: 0001104659-22-002739 · tm222382d1_4.xml · derivative · entry 2 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,913 Underlying: Common Stock · 17,913 shares Expires 2032-01-06 F2 · derivative.exercise_date: This option shall vest in 48 equal monthly installments subject to continued service to the company by the Reporting Person. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 21:22 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantCommon Stock | 5,748 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-002739 · tm222382d1_4.xml · nonDerivative · entry 1 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,748 F1 · security: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 6, 2023, another thirty three percent (33%) to vest on January 6, 2024 and the remaining thirty four percent (34%) to vest on January 6, 2025, such that the restricted stock awards are fully vested on January 6, 2025. F1 · kind: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 6, 2023, another thirty three percent (33%) to vest on January 6, 2024 and the remaining thirty four percent (34%) to vest on January 6, 2025, such that the restricted stock awards are fully vested on January 6, 2025. F1 · price: This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 6, 2023, another thirty three percent (33%) to vest on January 6, 2024 and the remaining thirty four percent (34%) to vest on January 6, 2025, such that the restricted stock awards are fully vested on January 6, 2025. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 14:29 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $70.68 | $0.00 |
DisclosureSEC source: 0001104659-21-002791 · tm2022926-9_4seq1.xml · derivative · entry 2 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2031-01-07 F2 · derivative.exercise_date: This option shall vest in 48 equal monthly installments subject to continued service to the Company by the Reporting Person. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 14:29 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-002791 · tm2022926-9_4seq1.xml · nonDerivative · entry 1 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Represents restricted stock awards. The restricted stock awards shall vest as follows: thirty three percent (33%) to vest on January 7, 2022, another thirty three percent (33%) to vest on January 7, 2023 and the remaining thirty four percent (34%) to vest on January 7, 2024, such that the restricted stock awards are fully vested on January 7, 2024. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 00:20 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantStock Option (Right to Buy) · Derivative | 78,300 | $0.00 Strike: $25.45 | $0.00 |
DisclosureSEC source: 0001104659-19-069637 · tm1924457-1_form4.xml · derivative · entry 1 Nofi Michael · CIK 0001705477 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,300 Underlying: Common Stock · 78,300 shares Expires 2029-12-02 F1 · derivative.exercise_date: This option shall vest as follows: 25% of the option shall vest on December 2, 2020; and the remaining 75% shall vest in equal monthly installments thereafter for a period of three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.